De novo malignancy post-liver transplantation: A single center, population controlled study

Hemant Chatrath, Kenneth Berman, Raj Vuppalanchi, James Slaven, Paul Kwo, A. Joseph Tector, Naga Chalasani, Marwan Ghabril

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: With the growing numbers of liver transplant recipients, it is increasingly important to understand the risks of de novo malignancy after liver transplantation. Aim: To characterize the incidence of de novo malignancy after liver transplantation compared with a control non-transplant population. Methods: We studied 534 Indiana state residents undergoing liver transplantation at our center between 1997 and 2004, followed through August 2010. The incidence and predictors of malignancy were determined. The standardized incidence ratio (SIR) of cancer in our cohort was compared with age-, gender-, and period-matched state population using the Indiana State Cancer Registry. Results: After a mean follow-up of 5.7 ± 3.2 yr, 73 patients (13.7%) developed 80 cancers, with five- and 10-yr incidence rates of 11.7% and 24.8%, respectively. These included 24 (30%) skin, 16 (20%) hematologic, and 40 (50%) solid tumors. The most common solid cancers were aerodigestive. Compared with matched state population, liver transplant recipients had significantly higher incidence of all cancers (SIR: 3.1, 95% CI [Confidence interval]: 2.9-3.2), skin (melanoma) (SIR: 5.8, 95% CI: 4.7-7.0), hematologic (SIR: 7.1, 95% CI: 6.3-8.0), and solid (SIR: 2.7, 95% CI: 2.5-2.8) tumors. Conclusion: There is a significantly increased risk of de novo malignancies after liver transplantation, highlighting the need for surveillance strategies in this population.

Original languageEnglish
Pages (from-to)582-590
Number of pages9
JournalClinical Transplantation
Volume27
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

Liver Transplantation
Population
Incidence
Neoplasms
Confidence Intervals
Skin
Liver
Registries
Melanoma

Keywords

  • de novo
  • Liver transplantation
  • Malignancy
  • Population control study
  • Standardized incidence ratio

ASJC Scopus subject areas

  • Transplantation

Cite this

De novo malignancy post-liver transplantation : A single center, population controlled study. / Chatrath, Hemant; Berman, Kenneth; Vuppalanchi, Raj; Slaven, James; Kwo, Paul; Tector, A. Joseph; Chalasani, Naga; Ghabril, Marwan.

In: Clinical Transplantation, Vol. 27, No. 4, 07.2013, p. 582-590.

Research output: Contribution to journalArticle

Chatrath, Hemant ; Berman, Kenneth ; Vuppalanchi, Raj ; Slaven, James ; Kwo, Paul ; Tector, A. Joseph ; Chalasani, Naga ; Ghabril, Marwan. / De novo malignancy post-liver transplantation : A single center, population controlled study. In: Clinical Transplantation. 2013 ; Vol. 27, No. 4. pp. 582-590.
@article{14653ef5df98410caa1bd7d7e1108203,
title = "De novo malignancy post-liver transplantation: A single center, population controlled study",
abstract = "Background: With the growing numbers of liver transplant recipients, it is increasingly important to understand the risks of de novo malignancy after liver transplantation. Aim: To characterize the incidence of de novo malignancy after liver transplantation compared with a control non-transplant population. Methods: We studied 534 Indiana state residents undergoing liver transplantation at our center between 1997 and 2004, followed through August 2010. The incidence and predictors of malignancy were determined. The standardized incidence ratio (SIR) of cancer in our cohort was compared with age-, gender-, and period-matched state population using the Indiana State Cancer Registry. Results: After a mean follow-up of 5.7 ± 3.2 yr, 73 patients (13.7{\%}) developed 80 cancers, with five- and 10-yr incidence rates of 11.7{\%} and 24.8{\%}, respectively. These included 24 (30{\%}) skin, 16 (20{\%}) hematologic, and 40 (50{\%}) solid tumors. The most common solid cancers were aerodigestive. Compared with matched state population, liver transplant recipients had significantly higher incidence of all cancers (SIR: 3.1, 95{\%} CI [Confidence interval]: 2.9-3.2), skin (melanoma) (SIR: 5.8, 95{\%} CI: 4.7-7.0), hematologic (SIR: 7.1, 95{\%} CI: 6.3-8.0), and solid (SIR: 2.7, 95{\%} CI: 2.5-2.8) tumors. Conclusion: There is a significantly increased risk of de novo malignancies after liver transplantation, highlighting the need for surveillance strategies in this population.",
keywords = "de novo, Liver transplantation, Malignancy, Population control study, Standardized incidence ratio",
author = "Hemant Chatrath and Kenneth Berman and Raj Vuppalanchi and James Slaven and Paul Kwo and Tector, {A. Joseph} and Naga Chalasani and Marwan Ghabril",
year = "2013",
month = "7",
doi = "10.1111/ctr.12171",
language = "English",
volume = "27",
pages = "582--590",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - De novo malignancy post-liver transplantation

T2 - A single center, population controlled study

AU - Chatrath, Hemant

AU - Berman, Kenneth

AU - Vuppalanchi, Raj

AU - Slaven, James

AU - Kwo, Paul

AU - Tector, A. Joseph

AU - Chalasani, Naga

AU - Ghabril, Marwan

PY - 2013/7

Y1 - 2013/7

N2 - Background: With the growing numbers of liver transplant recipients, it is increasingly important to understand the risks of de novo malignancy after liver transplantation. Aim: To characterize the incidence of de novo malignancy after liver transplantation compared with a control non-transplant population. Methods: We studied 534 Indiana state residents undergoing liver transplantation at our center between 1997 and 2004, followed through August 2010. The incidence and predictors of malignancy were determined. The standardized incidence ratio (SIR) of cancer in our cohort was compared with age-, gender-, and period-matched state population using the Indiana State Cancer Registry. Results: After a mean follow-up of 5.7 ± 3.2 yr, 73 patients (13.7%) developed 80 cancers, with five- and 10-yr incidence rates of 11.7% and 24.8%, respectively. These included 24 (30%) skin, 16 (20%) hematologic, and 40 (50%) solid tumors. The most common solid cancers were aerodigestive. Compared with matched state population, liver transplant recipients had significantly higher incidence of all cancers (SIR: 3.1, 95% CI [Confidence interval]: 2.9-3.2), skin (melanoma) (SIR: 5.8, 95% CI: 4.7-7.0), hematologic (SIR: 7.1, 95% CI: 6.3-8.0), and solid (SIR: 2.7, 95% CI: 2.5-2.8) tumors. Conclusion: There is a significantly increased risk of de novo malignancies after liver transplantation, highlighting the need for surveillance strategies in this population.

AB - Background: With the growing numbers of liver transplant recipients, it is increasingly important to understand the risks of de novo malignancy after liver transplantation. Aim: To characterize the incidence of de novo malignancy after liver transplantation compared with a control non-transplant population. Methods: We studied 534 Indiana state residents undergoing liver transplantation at our center between 1997 and 2004, followed through August 2010. The incidence and predictors of malignancy were determined. The standardized incidence ratio (SIR) of cancer in our cohort was compared with age-, gender-, and period-matched state population using the Indiana State Cancer Registry. Results: After a mean follow-up of 5.7 ± 3.2 yr, 73 patients (13.7%) developed 80 cancers, with five- and 10-yr incidence rates of 11.7% and 24.8%, respectively. These included 24 (30%) skin, 16 (20%) hematologic, and 40 (50%) solid tumors. The most common solid cancers were aerodigestive. Compared with matched state population, liver transplant recipients had significantly higher incidence of all cancers (SIR: 3.1, 95% CI [Confidence interval]: 2.9-3.2), skin (melanoma) (SIR: 5.8, 95% CI: 4.7-7.0), hematologic (SIR: 7.1, 95% CI: 6.3-8.0), and solid (SIR: 2.7, 95% CI: 2.5-2.8) tumors. Conclusion: There is a significantly increased risk of de novo malignancies after liver transplantation, highlighting the need for surveillance strategies in this population.

KW - de novo

KW - Liver transplantation

KW - Malignancy

KW - Population control study

KW - Standardized incidence ratio

UR - http://www.scopus.com/inward/record.url?scp=84881559360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881559360&partnerID=8YFLogxK

U2 - 10.1111/ctr.12171

DO - 10.1111/ctr.12171

M3 - Article

C2 - 23808800

AN - SCOPUS:84881559360

VL - 27

SP - 582

EP - 590

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4

ER -